Smart medication management service based on additive manufacturing for elderly patients - (SmartDose)

基于增材制造的老年患者智能用药管理服务——（SmartDose）

• 批准号: 83030
• 金额: $ 49.41万
• 依托单位: FABRX LIMITED
• 依托单位国家: 英国
• 项目类别: CR&D Bilateral
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=83030
• 关键词: Smart; medication; management; service; based

Age-UK found that 2 million people over the age of 65 are taking at least seven prescribed medicines per day. The number of prescribed medications taken increases as people age. Consistent managing and consumption of medications is important for successful recovery or continued management of a chronic illness and disease.This project will develop SmartDose, an integrated solution that allows doctors to prescribe custom medication to patients, allows pharmacies to manufacture this medication and patients to conveniently collect and take this medication in a smart pill dispenser device. SmartDose will use a 3D pharmaceutical printer to print the custom medication, with the doctor specifying the shapes, colours, sizes, and doses based on an individual patient's need.The consortium is led by FabRx, a specialist biotech company, focused on developing 3D printing technology for fabricating pharmaceuticals and medical devices. They are joined by Brunel University London (BUL), who have developed ultrasonic and imaging technology that can improve the printing process. Our Eureka partner, Yongatek, are a research and development company who have developed products for the healthcare sector and will develop the prototype system.

AGE-UK发现，有200万65岁以上的人每天至少服用七种处方药。随着年龄的增长，服用处方药的数量也在增加。对药物的持续管理和消耗对于慢性病的成功康复或持续管理非常重要。该项目将开发SmartDose，这是一种集成解决方案，允许医生为患者开出定制的药物，允许药店生产这种药物，患者可以在智能药片分发机设备中方便地收集和服用这种药物。SmartDose将使用3D药物打印机打印定制药物，医生根据患者的个人需求指定形状、颜色、大小和剂量。该联盟由专门的生物技术公司FabRx领导，专注于开发3D打印技术，用于制造药物和医疗设备。伦敦布鲁内尔大学(BUL)也加入了他们的行列，他们开发了可以改进打印过程的超声波和成像技术。我们的尤里卡合作伙伴永泰克是一家研发公司，已经为医疗保健部门开发了产品，并将开发原型系统。